TY - JOUR
T1 - Evaluation of Antibody Responses in Patients with B-Cell Malignancies after Two and Three Doses of Anti-SARS-CoV-2 S Vaccination—A Retrospective Cohort Study
AU - Wirth, Stella Rosa Maria
AU - Podar, Klaus
AU - Pecherstorfer, Martin
AU - Wohlfarth, Philipp
AU - Jaeger, Ulrich
AU - Singer, Josef
N1 - Funding Information:
S.R.M.W. and P.W. have no conflicts of interest with regard to this work. K.P. is the recipient of the Technopol grant WST3-F-5031298/002-2018 (K.P.) and WST3-F-5031 298/003-2019, as well as a research support grant from Roche Pharmaceuticals. K.P. declares no known competing financial interests or personal relationships that could have influenced the work reported in this paper. M.P. declares financial support from Roche for research projects. U.J. declares consultancy from Novartis and Janssen and honoraria for advisory boards from Novartis, Gilead, Miltenyi, BMS and Janssen. J.S. declares honorarium payments from Abbvie, Amgen, Gilead, Janssen, Merck, Merck Sharp & Dohme, Novartis, Pfizer, Roche and Servier as an invited speaker or expert consulting on other topics than anti-SARS-CoV-2 vaccines and B-cell malignancies.
Funding Information:
The authors appreciate the contribution of NÖ Landesgesundheitsagentur, the legal entity of University Hospitals in Lower Austria, for providing the organizational framework to conduct this research. They would also like to acknowledge the support by the Open Access Publishing Fund of Karl Landsteiner University of Health Sciences, Krems, Austria. KP is the recipient of the Technopol grant WST3-F-5031298/002-2018 (KP) and the WST3-F-5031 298/003-2019 as well as of a research support grant from Roche Pharmaceuticals. U.J. received funding from the Innovative Medicines Initiative Joint Undertaking, under grant agreement no. 116026 (T2EVOLVE). This Joint Undertaking received support from the European Union’s Horizon 2020 Research and Innovation Program and EFPIA.
Publisher Copyright:
© 2023 by the authors.
PY - 2023/1/14
Y1 - 2023/1/14
N2 - Patients with B-cell malignancies are at a higher risk of severe SARS-CoV-2 infections. Nevertheless, extensive data on the immune responses of hematological patients and the efficacy of the third dose of the vaccine are scarce. The goal of this study was to determine standardized anti-SARS-CoV-2 S antibody levels and to evaluate differences between treatment modalities in response to the second and third vaccines among patients with B-cell malignancies treated at the University Hospital Krems and the University Hospital of Vienna. The antibody levels of a total of 80 patients were retrospectively analyzed. The results indicate a significant increase in antibody production in response to the third vaccination. The highest increases could be observed in patients in a “watchful-waiting” and “off-therapy” setting. Encouragingly, approximately one-third of patients who did not develop antibodies in response to two vaccinations achieved seroconversion after the third vaccination. “Watchful-waiting”, “off-therapy” and treatment with BTK inhibitors were indicative for increased antibody response after the third dose compared to anti-CD19 CAR T-cell and anti-CD-20 antibody treatment. In summary, the results of this study underline the pre-eminent role of the need for complete vaccination with three doses for the development of protective immunity in patients with B-cell malignancies.
AB - Patients with B-cell malignancies are at a higher risk of severe SARS-CoV-2 infections. Nevertheless, extensive data on the immune responses of hematological patients and the efficacy of the third dose of the vaccine are scarce. The goal of this study was to determine standardized anti-SARS-CoV-2 S antibody levels and to evaluate differences between treatment modalities in response to the second and third vaccines among patients with B-cell malignancies treated at the University Hospital Krems and the University Hospital of Vienna. The antibody levels of a total of 80 patients were retrospectively analyzed. The results indicate a significant increase in antibody production in response to the third vaccination. The highest increases could be observed in patients in a “watchful-waiting” and “off-therapy” setting. Encouragingly, approximately one-third of patients who did not develop antibodies in response to two vaccinations achieved seroconversion after the third vaccination. “Watchful-waiting”, “off-therapy” and treatment with BTK inhibitors were indicative for increased antibody response after the third dose compared to anti-CD19 CAR T-cell and anti-CD-20 antibody treatment. In summary, the results of this study underline the pre-eminent role of the need for complete vaccination with three doses for the development of protective immunity in patients with B-cell malignancies.
UR - http://www.scopus.com/inward/record.url?scp=85146744484&partnerID=8YFLogxK
U2 - 10.3390/cancers15020524
DO - 10.3390/cancers15020524
M3 - Journal article
C2 - 36672473
SN - 2072-6694
VL - 15
SP - 524
JO - Cancers
JF - Cancers
IS - 2
M1 - 524
ER -